StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck organon — Marvelon / Mercilon (oral contraceptives) U.S. sales ($M) ($M)

Organon & Co. Form 10-Q / 10-K (CIK 0001821825)

Latest, Q2 2026
0
Period ended Jun 30, 2026
Change on a year earlier
–
0 in Q2 2025
History
18 quarters
Since Q1 2022
Sources
13
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Merck Organon — Marvelon / Mercilon (oral contraceptives) U.S. sales ($M) ($M), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn_marvelonmercilon_us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.